<DOC>
	<DOC>NCT00746811</DOC>
	<brief_summary>The objectives of this study are to assess the effects of 4 g/d P-OM3, compared with placebo, on LDL-C and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia.</brief_summary>
	<brief_title>Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia</brief_title>
	<detailed_description>This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2 (Week 0), subjects meeting all entry criteria will be randomized to one of two treatment sequences: placebo or P-OM3 for the first 6 week phase followed by the study product they did not receive during the first phase (P-OM3 or placebo) for the second 6 weeks.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Men and women, ages 1879 inclusive Fasting, untreated lowdensity lipoprotein cholesterol (LDLC)level in the borderline high to very high range Fasting, untreated triglyceride (TG)level in the normal range Provide written informed consent and authorization for protected health information CHD or CHD risk equivalent Pregnancy Use of lipid altering medications which cannot be stopped Body mass index over 45 kg per square meter Allergy or sensitivity to omega3 fatty acids Certain muscle, liver, kidney, lung or gastrointestinal conditions Poorly controlled hypertension Certain medications Active cancers treated within prior 2 years (except nonmelanoma skin cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>omega 3</keyword>
</DOC>